Abstract
Multiple sclerosis (MS) is characterized by demyelinating lesions disseminated throughout the central nervous system, and a progressive axonal degeneration. In this review we propose that an impaired cAMP signaling in white mater astrocytes, caused by a deficiency of β2-adrenergic receptors, may play a role in the pathogenesis of the disease. Reduced astrocytic cAMP signaling may, in a proinflammatory environment, facilitate astrocytes to become facultative antigen presenting cells, stimulating the development of inflammatory demyelinating lesions. It may reduce astrocytic glycogenolysis, which supplies energy and N-acetylaspartate (NAA) to axons and oligodendrocytes, reduce trophic and neuroprotective support to oligodendrocytes and neurons, and enhance astrogliosis.
Keywords: Multiple sclerosis, astrocytes, β2-adrenergic receptors, cAMP, demyelination, axonal degeneration, astrocyte signaling, immune hypothesis, impaired energy metabolism, plasma cells
Current Signal Transduction Therapy
Title: Astrocyte Signaling and Multiple Sclerosis
Volume: 7 Issue: 1
Author(s): Miguel D'haeseleer, Melissa Cambron and Jacques De Keyser
Affiliation:
Keywords: Multiple sclerosis, astrocytes, β2-adrenergic receptors, cAMP, demyelination, axonal degeneration, astrocyte signaling, immune hypothesis, impaired energy metabolism, plasma cells
Abstract: Multiple sclerosis (MS) is characterized by demyelinating lesions disseminated throughout the central nervous system, and a progressive axonal degeneration. In this review we propose that an impaired cAMP signaling in white mater astrocytes, caused by a deficiency of β2-adrenergic receptors, may play a role in the pathogenesis of the disease. Reduced astrocytic cAMP signaling may, in a proinflammatory environment, facilitate astrocytes to become facultative antigen presenting cells, stimulating the development of inflammatory demyelinating lesions. It may reduce astrocytic glycogenolysis, which supplies energy and N-acetylaspartate (NAA) to axons and oligodendrocytes, reduce trophic and neuroprotective support to oligodendrocytes and neurons, and enhance astrogliosis.
Export Options
About this article
Cite this article as:
D'haeseleer Miguel, Cambron Melissa and De Keyser Jacques, Astrocyte Signaling and Multiple Sclerosis, Current Signal Transduction Therapy 2012; 7 (1) . https://dx.doi.org/10.2174/157436212799278133
DOI https://dx.doi.org/10.2174/157436212799278133 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Tetrahydrobioterin (BH4) Pathway: From Metabolism to Neuropsychiatry
Current Neuropharmacology Has Bevacizumab (Avastin) Given Extra Therapeutic Gain in Metastatic Colorectal Cancer and Malignant Brain Gliomas? Systematic Review Answering this Question
Recent Patents on Inflammation & Allergy Drug Discovery The Biology of the Sodium Iodide Symporter and its Potential for Targeted Gene Delivery
Current Cancer Drug Targets Dependence of DPPH Radical Scavenging Activity of Dietary Flavonoid Quercetin on Reaction Environment
Mini-Reviews in Medicinal Chemistry Bicycloheptylamine-Doxorubicin Conjugate: Synthesis and Anticancer Activities in σ2 Receptor-Expressing Cell Lines
Medicinal Chemistry Critical Questions for Preclinical Trials on Safety and Efficacy of Vascular Endothelial Growth Factor-Based Therapeutic Angiogenesis for Ischemic Stroke
CNS & Neurological Disorders - Drug Targets Application of In Vivo Electroporation to Cancer Gene Therapy
Current Gene Therapy Plant Coumestans: Recent Advances and Future Perspectives in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry A Review of Studies on Targeting Interleukin 4 Receptor for Central Nervous System Malignancy
Current Molecular Medicine TGFß, a Potent Regulator of Tumor Microenvironment and Host Immune Response, Implication for Therapy
Current Molecular Medicine Impact of Drug Metabolism/Pharmacokinetics and their Relevance Upon Taxus-based Drug Development
Current Drug Metabolism Evaluation of the in vivo Safety Profiles of Rictor Inhibition Using a Zebrafish Model
Current Pharmaceutical Design Recent Advances in Characterizing Natural Products that Regulate Autophagy
Anti-Cancer Agents in Medicinal Chemistry Synthesis of Prenylated Xanthones: An Overview
Current Organic Chemistry Malignant Glioma In Vitro Models: On the Utilization of Stem-like Cells
Current Cancer Drug Targets Flavonoids: The Innocuous Agents Offering Protection against Alzheimer’s Disease Through Modulation of Proinflammatory and Apoptotic Pathways
Current Topics in Medicinal Chemistry A Nanostructured Silica-Lipid Hybrid to Facilitate Oral SN-38-based Chemotherapy
Drug Delivery Letters The Development of Copper Radiopharmaceuticals for Imaging and Therapy
Medicinal Chemistry Editorial [Hot Topic: Nongenomic Effects of Thyroid Hormones in Central Nervous System and Skeletal Muscle (Guest Editor: Sandra Incerpi)]
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Neuroprotection for Amyotrophic Lateral Sclerosis: Role of Stem Cells, Growth Factors, and Gene Therapy
Central Nervous System Agents in Medicinal Chemistry